Immunity against post-translationally modified proteins in autoimmune diseases

Beukel, M.D. van den



2

Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association

van den Beukel MD, van Wesemael TJ, Hoogslag ATW, Borggreven NV, Huizinga TW, van der Helm-van Mil AH, Toes RE, van der Woude D, Trouw LA.

RMD Open. 2023 Dec 1;9(4):e003480.
doi: 10.1136/rmdopen-2023-003480.

Key messages

What is already known?

Rheumatoid arthritis (RA) patients can be divided into seropositive and seronegative subgroups. The presence of antibodies against post-translationally modified (PTM) proteins such as citrullinated proteins is nowadays used as a diagnostic and prognostic marker in RA. Antibodies directed against carbamylated proteins have more recently been shown to be present in a subset of the seronegative patients and are associated with bone erosions in that group.

What does this study add?

In this study, two different anti-PTM antibodies are investigated: anti-Advanced Glycation End-product modified protein antibodies (anti-AGE) and anti-Malondialdehyde-Acetaldehyde Adduct modified protein antibodies (anti-MAA). These antibodies can be detected in several forms of inflammatory arthritis. Within seronegative RA (negative for rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and anti-carbamylated protein antibodies (anti-CarP)), 16.9% percent of patients are positive for anti-MAA and/or anti-AGE antibodies. This subgroup is characterized by an association with HLA-DRB1*03, increased radiographic joint damage, and (for anti-MAA) inflammation.

How might this impact on clinical practice or future developments?

The presence of anti-PTM antibodies like anti-AGE and anti-MAA in RA patients and other inflammatory arthritis patients previously considered to be seronegative, may not only serve as a prognostic marker, but importantly may contribute to understanding the pathogenesis of these conditions, including a subset of RA.

Abstract

Objective

In rheumatoid arthritis (RA) around two-thirds of patients are autoantibody-positive for rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and/or anti-carbamylated protein antibodies (anti-CarP). The remaining seronegative subgroup of patients is clinically heterogeneous and thus far, biomarkers predicting the disease course are lacking. Therefore, we analyzed the value of other autoantibodies in RA directed against malondialdehyde-acetaldehyde adducts (MAA) and advanced glycation end-products (AGE).

Methods

In sera of 648 RA patients and 538 non-RA arthritis patients from the Leiden Early Arthritis Clinic, anti-MAA and anti-AGE IgG antibody levels were measured using ELISA. Associations between genetic risk factors, acute phase reactants, radiological joint damage, remission and anti-PTM positivity were investigated using regression, correlation and survival analyses.

Results

Anti-AGE and anti-MAA were most prevalent in RA (44.6% and 46.1% respectively) but were also present in non-RA arthritis patients (32.9% and 30.3% respectively). Anti-AGE and anti-MAA antibodies were associated with HLA-DRB1*03 within seronegative RA (OR=1.98, p=0.003, and OR=2.37, p<0.001, respectively) and, for anti-AGE also in non-RA arthritis patients (OR=2.34, p<0.001). Presence of anti-MAA antibodies was associated significantly with markers of inflammation, ESR and CRP, in all groups independent of anti-AGE. Interestingly, the presence of anti-AGE and anti-MAA antibodies was associated with radiologic progression in seronegative RA patients, but not evidently with sustained drug-free remission.

Conclusions

Anti-AGE and anti-MAA were present in around 45% of RA patients and 30% of non-RA patients, and although not specific for RA, their presence associated with HLA, inflammation and, for RA, with clinical outcomes especially in seronegative RA patients.

Introduction

In rheumatoid arthritis (RA) around two-thirds of patients are autoantibody-positive for rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA) and/or anti-carbamylated protein (anti-CarP) antibodies (1). The remaining seronegative subgroup of RA is clinically heterogeneous and thus far no reliable biomarkers are available to identify these patients or predict their disease course (1).

ACPA and anti-CarP are antibodies that recognize proteins that have undergone post-translational modification (PTM), citrullination of arginine and carbamylation of lysine respectively (2, 3). However, many other types of PTMs exist (4). Two examples of PTMs that are found to associate with disease are Advanced Glycation End-products (AGE) and Malondialdehyde-Acetaldehyde Adducts (MAA). AGEs are a result of oxidative stress and tissue damage (5) and are for example present in patients with diabetes mellitus type 2 (6). Interestingly, in these patients also antibodies directed against this PTM were observed (6). MAA modifications are a result of reactive oxygen species (ROS) that are formed during inflammation and oxidative stress (7). MAA modified proteins as well as anti-MAA antibodies are found in patients with RA, as well as in other diseases (7). AGE and MAA are both highly immunogenic PTMs (8, 9). Therefore it is plausible that antibodies against AGE and MAA are also present in patients with arthritis.

Seronegative RA is associated with HLA-DRB1*03, suggesting a role for immunopathology driven by e.g. B cell immunity (10). Indeed, within the ACPA-negative patients the presence of anti-CarP was associated with HLA-DRB1*03 (11, 12). However, it did not yet explain the full HLA-DRB1*03 association, raising the possibility that other anti-PTM responses may be present in 'seronegative' RA that are present in the remainder of the HLA-DRB1*03 positive individuals (13, 14). On top of this haplotype association, within these ACPA-negative RA patients anti-CarP was found to associate with a more severe radiological progression (3). Seronegative RA patients are a diverse group of patients that in many ways resemble undifferentiated arthritis. Presence of antibodies, like anti-PTM antibodies, might help to better understand and characterize subgroups that possibly belong to this so called seronegative RA.

We therefore investigated whether anti-AGE and anti-MAA antibodies are present in patients with RA and other forms of arthritis, and whether they could potentially close the so-called serological gap (1) in seronegative RA.

Methods

Patients

1186 patients with arthritis of at least one joint and a symptom duration of less than 2 years were included in the Leiden Early Arthritis Clinic (EAC) cohort (15). Data was collected at baseline and follow-up (4, 12 months and yearly thereafter). Patients were being followed as long as the patient remained being seen clinically by the rheumatologist. RA was classified based on the 1987 ACR criteria (n=648) (16). Definitive diagnoses other than RA (n=538), were made by the treating physician after 1 year of follow-up and were predominantly psoriatic arthritis (PsA) (n=100), inflammatory osteoarthritis (OA) (n=95) and gout (n=93) besides other more rare forms of arthritis. For this manuscript, the following diagnoses were termed autoimmune (AI): RA, psoriatic arthritis, spondyloarthritis, sarcoidosis, systemic lupus erythematosus (SLE) and paraneoplastic arthritis. The diagnoses termed as non-autoimmune (non-AI) were: gout, pseudogout and septic arthritis. The protocols were approved by the Leiden University Medical Center ethics committee and written informed consent was obtained. Clinical and demographic patient characteristics were collected as described previously (17).

Genotyping, radiological progression and remission

From all patients, HLA genotypes were established as described previously (18). The alleles that were marked as shared epitope-encoding HLA (HLA-SE) positive were: HLA-DRB1*01:01, 01:02, 04:01, 04:04, 04:05, 04:08, 10:01, 14:02. For the radiological progression analyses, 2853 X-ray sets of the hands and feet of 635 RA patients were scored as described previously using the Sharp-van der Heijde score (SHS) (19, 20). Sustained drug-free remission (SDFR) was defined as absence of clinical synovitis after discontinuation of disease-modifying antirheumatic drug (DMARD) treatment, that persisted for the entire follow-up, being at least 1 year (21).

Anti-AGE and anti-MAA measurements

Anti-AGE and anti-MAA antibodies were detected using an in-house ELISA based on modified fetal calf serum (FCS) as described previously (22). Briefly, modified and non-modified FCS were coated to a Nunc Maxisorp ELISA plate (430341, Thermofisher). In between each sequential step plates were washed 3 times using Phosphate Buffered Saline (PBS)/0.05%Tween (Sigma, P1379). After blocking (PBS/1%Bovine Serum Albumin (BSA)) for 6 hours at 4°C plates were incubated overnight at 4°C with 1/100 or 1/1000 diluted serum for anti-AGE and anti-MAA respectively. Each plate contained a standard of anti-PTM positive serum to calculate arbitrary units. After incubation, IgG levels were detected using Rabbit-anti-Human IgG-HRP (Dako, P0214). Plates were developed by incubating with 2,2'-azino-bis[3-ethylbenzothiazoline-6-sulfonic acid] (ABTS)/0.015% H2O2 (A1888 and 7722-84-1, both from Merck) and absorbance at 415nm was measured

using a microplate reader (Bio-Rad iMark). The cut-off for positivity was set as the mean arbitrary units plus two times the standard deviation of 80 healthy controls, excluding values higher than 10x the mean.

Statistical analysis

Independent samples T-test and Mann-Whitney U tests were used to analyze the baseline characteristics. The association of HLA-DRB1*03 with autoantibodies was assessed with logistic regression, and stratified for anti-cyclic citrullinated peptide 2 (anti-CCP2) and anti-CarP if relevant. Correlations between anti-PTM antibodies and inflammatory markers were calculated using Spearman's rank correlation. For the radiologic progression analyses, a multivariate normal regression model for longitudinal data was used with SHS as response variable. The model controlled for the age, sex, and inclusion-year of the patients (19). SDFR-development until follow-up was calculated using Kaplan Meier survival analysis and Cox's regression. All statistical analysis were performed using SPSS statistics version 25 (IBM).

Results

Anti-AGE and anti-MAA in arthritis patients

Baseline characteristics are described in *Table 1*. Anti-PTM antibody levels were measured in RA and non-RA arthritis patients and compared to healthy controls (*Figure 1A and B, and Supplementary Table 1)*. The non-RA arthritis group was divided into subgroups and separately depicted based as Auto-Immune (AI) arthritis (without RA) including psoriatic arthritis, paraneoplastic arthritis, SLE, sarcoidosis and spondyloarthritis and as non-Auto-Immune (non-AI) arthritis including septic arthritis, gout and pseudogout.

Compared to healthy controls anti-AGE and anti-MAA were most prevalent in RA (anti-AGE: 7.5% in HC versus 44.6% in RA and anti-MAA: 3.8% in HC versus 46.1% in RA but were also present in other types of early arthritis. Within non-RA arthritis patients anti-AGE and anti-MAA were present in 32.9% and 30.3%, respectively and in non-RA autoimmune arthritis anti-AGE and anti-MAA were found in 38.5% and 41.5% respectively. These data indicate that the presence of anti-PTM antibodies is not specific for RA. When analyzing combinations of autoantibodies, the largest subgroup of RA patients (n=99) had all four anti-PTM antibodies (anti-AGE, anti-MAA, anti-CarP, anti-CCP2) as well as RF, after which the second largest group (n=63) was characterized by the combination of RF, anti-CCP2 and anti-CarP (*Figure 1C*).

Interestingly, 67 (34.0%) and 57 (28.9%) of seronegative (RF-, ACPA- and anti-CarP negative) RA patients were positive for anti-AGE and anti-MAA respectively. Moreover, 40 (20.3%) of

these seronegative RA patients were positive for both anti-AGE and anti-MAA. These anti-PTM responses may identify a new subgroup in the otherwise seronegative RA patients.



Figure 1: Anti-AGE and anti-MAA show higher levels in RA and occur in a subgroup of anti-CarP anti-CCP2 negative RA patients. IgG antibody levels of anti-AGE (A) and anti-MAA (B) in patients with (n=648) and without (n=538) RA. Early arthritis patients were separately depicted as groups: AI without RA (including psoriatic arthritis, paraneoplastic arthritis, SLE, sarcoidosis and spondyloarthritis) and non-AI (including septic arthritis, gout, pseudogout). (C) Upset plots of groups of RA patients (n=499*) positive for anti-PTM combinations; anti-AGE, anti-MAA, anti-CarP, anti-CCP2 and RF. *data for anti-CarP was missing for 149 RA patients. *Abbreviations: AGE, Advanced Glycation End-product; aU/mL, Arbitrary Units per mL; AI, autoimmune; CarP, Carbamylated Protein; CCP2, citrullinated cyclic peptide 2; MAA, Malondialdehyde Acetaldehyde Adduct; RA, Rheumatoid Arthritis; RF, Rheumatoid Factor.*

Table 1: Baseline characteristics of the RA, non-RA arthritis, autoimmune no RA and non-autoimmune group.

	RA (n=648)*	non-RA (n=538)*	AI no RA (n=233)*	non-AI (n=226)*
Female (n,%)	432 (66.7%)	269 (50.0%)	165 (49.8%)	112 (49.6%)
Age (mean, SD)	57.3 (17.4)	50.9 (15.8)	43.9 (15.7)	61.2 (13.5)
BMI (mean, SD)	25.9 (3.9)	26.5 (4.5)	25.7 (4.3)	27.5 (4.4)
Sympt. Dur. Weeks (median, IQR)	18 (9-36)	9 (2-27)	11 (4 – 28)	10 (2 – 31)
SJC (in 28joints) (median, IQR)	6 (3 - 11)	1 (1 - 4)	2 (0 - 4)	1 (1 – 4)
TJC (in 28joints) (median, IQR)	8 (4 - 14)	4 (1 - 9)	5 (2 – 9)	4 (1 – 8)
VAS (0-100) (median, IQR)	42 (20 – 58)	40 (19-60)	40 (20 – 60)	35 (19 – 52)
ESR (median, IQR)	34 (19 - 54)	27 (11 - 50)	33 (13 – 56)	19 (9 – 37)
CRP (median, IQR)	18 (8 - 41)	13 (4 - 34)	18 (6 – 41)	9 (3 – 23)
HAQ (median, IQR)	1 (0.62-1.62)	0.75 (0.25-1.13)	0.63 (0.25 – 1.13)	0.75 (0.25 – 1.13)
Smoking+ (n,%)	159 (24.5%)	102 (19.0%)	63 (20.5%)	41 (20.8%)
HLA-SE+ (n,%)	410 (63.3%)	128 (23.8%)	411 (48.5%)	N/A**
ACPA	317 (51.3%)	22 (5.1%)	17 (7.0%)	5 (2.7%)
RF	365 (56.3%)	52 (9.8%)	28 (10.4%)	24 (10.9%)

* = numbers differ slightly per analyses due to missing variables
** = data not shown (47.8% missing)
Diagnoses were termed non-RA: all diagnoses other than RA within the EAC cohort.
Diagnoses were termed autoimmune (AI) no RA: psoriatic arthritis, spondyloarthritis, sarcoidosis, SLE and paraneoplastic arthritis.
Diagnoses termed as non-autoimmune (non-AI) were: gout, pseudogout and septic arthritis.
Abbreviations: BMI, Body Mass Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; HLA-SE, HLA Shared Epitope; IQR, interquartile range; SD, standard deviation; SJC, swollen joint count; Sympt. Dur. Weeks, Symptom duration in weeks; TJC, tender joint count; VAS, visual analog scale.

HLA-DRB1*03 associates with anti-AGE and anti-MAA independently of anti-CarP in anti-CCP2-negative RA patients

Since HLA class II alleles are known to associate with autoantibody positivity in RA, we sought to investigate the presence of HLA-SE and its association with anti-AGE and anti-MAA antibodies. Of all RA patients 63.3% were HLA-SE+ (*Table 1*). Based on the well-known association between HLA-SE and RA, the HLA-SE alleles were assessed and were significantly more prevalent in all RA subgroups compared to healthy controls. In the anti-AGE-positive group, as compared to anti-AGE-negative RA patients however, the prevalence of HLA-SE alleles was similar (*Table 2*). The same was true for anti-MAA, therefore both anti-AGE and anti-MAA antibodies were not associated with HLA-SE.

Table 2: Association between anti-AGE and anti-MAA antibodies and HLA-SE and HLA-DRB1*03 presence in RA and HLA-DRB1*03 presence in non-RA patients from the Leiden EAC cohort.

Part I	**RA n=648**								
	HLA-SE-	**HLA-SE+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Healthy controls	674 (55.7)	537 (44.3)	1211	1 (ref)					
Anti-AGE-	139 (38.7%)	220 (61.3%)	359	**1.99**	**(1.56, 2.53)**	**<0.001**	1 (ref)		
Anti-AGE+	99 (34.3%)	190 (65.7%)	289	**2.41**	**(1.84, 3.15)**	**<0.001**	1.21	(0.88, 1.67)	0.24
Anti-MAA-	130 (37.2%)	219 (62.8%)	349	**2.11**	**(1.66, 2.70)**	**<0.001**	1 (ref)		
Anti-MAA+	108 (36.1%)	191 (63.9%)	299	**2.22**	**(1.71, 2.88)**	**<0.001**	1.04	(0.76, 1.45)	0.77
	HLA-DRB1*03-	**HLA-DRB1*03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Healthy controls	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-	-	-	-	-
Anti-AGE-	271 (75.5%)	88 (24.5%)	359	1.13	(0.86, 1.49)	0.38	1 (Ref)	-	-
Anti-AGE+	211 (73.0%)	78 (27.0%)	289	1.29	(0.96, 1.73)	0.09	1.14	(0.80, 1.62)	0.47
Anti-MAA-	266 (76.2%)	83 (23.8%)	349	1.09	(0.82, 1.44)	0.56	1 (ref)	-	-
Anti-MAA+	216 (72.2%)	83 (27.8%)	299	**1.34**	**(1.01, 1.78)**	**0.05**	1.23	(0.87, 1.75)	0.25
	non-RA n=246#								
	HLA-DRB1*03-	**HLA-DRB1*03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Healthy controls	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-	-	-	-	-
Anti-AGE-	99 (76.7%)	30 (23.3%)	129	1.06	(0.69, 1.62)	0.80	1 (Ref)	-	-
Anti-AGE+	70 (59.8%)	47 (40.2%)	117	**2.34**	**(1.58, 3.47)**	**<0.001**	**2.22**	**(1.28, 3.84)**	**0.01**
Anti-MAA-	97 (72.4%)	37 (27.6%)	134	1.33	(0.89, 1.99)	0.17	1 (ref)	-	-
Anti-MAA+	72 (64.3%)	40 (35.7%)	112	**1.94**	**(1.29, 2.92)**	**0.002**	1.46	(0.85, 2.50)	0.17

Table 2: Continued.

Part II	anti-CCP2-negative RA n=301##								
	HLA-DRB1*03-	**HLA-DRB1*03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Healthy controls	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-				
Anti-AGE- Anti-CarP-	125 (72.3%)	48 (27.7%)	173	1.34	(0.93, 1.92)	0.11	1 (ref)	-	-
Anti-AGE+ Anti-CarP-	60 (63.8%)	34 (36.2%)	94	**1.98**	**(1.27, 3.07)**	**0.003**	1.48	(0.86, 2.52)	0.16
Anti-AGE- Anti-CarP+	6 (50.0%)	6 (50.0%)	12	**3.49**	**(1.11, 10.89)**	**0.03**	2.60	(0.80, 8.47)	0.11
Anti-AGE+ Anti-CarP+	14 (50.0%)	14 (50.0%)	28	**3.49**	**(1.64, 7.40)**	**0.001**	**2.60**	**(1.16, 5.87)**	**0.02**
	anti-CCP2-negative RA n=307###								
	HLA-DRB1*03-	**HLA-DRB1*03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Healthy controls	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-				
Anti-MAA- Anti-CarP-	135 (73.8%)	48 (26.2%)	183	1.24	(0.87, 1.77)	0.24	1 (ref)	-	-
Anti-MAA+ Anti-CarP-	50 (59.5%)	34 (40.5%)	84	**2.37**	**(1.50, 3.74)**	**<0.001**	**1.91**	**(1.11, 3.30)**	**0.02**
Anti-MAA- Anti-CarP+	6 (42.9%)	8 (57.1%)	14	**4.65**	**(1.60, 13.51)**	**0.01**	**3.75**	**(1.24, 11.36)**	**0.02**
Anti-MAA+ Anti-CarP+	14 (53.8%)	12 (46.2%)	26	**2.99**	**(1.37, 6.54)**	**0.01**	**2.41**	**(1.04, 5.58)**	**0.04**

Table 2: Continued.

Part II	SE-negative RA n=271[##+]								
	HLA-DRB1*03-	**HLA-DRB1*03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Healthy controls	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-	-			
Anti-AGE- Anti-CarP-	110 (82.7)	23 (17.3)	133	0.73	0.46 – 1.17)	0.29	1 (ref)	-	-
Anti-AGE+ Anti-CarP-	36 (58.1)	26 (41.9)	62	**2.52**	**(1.49 – 4.24)**	**<0.001**	**3.45**	**(1.76 – 6.79)**	**<0.001**
Anti-AGE- Anti-CarP+	23 (59.0)	16 (41.0)	39	**2.42**	**(1.26 - 4.66)**	**0.008**	**3.33**	**(1.52 – 7.26)**	**0.003**
Anti-AGE+ Anti-CarP+	23 (62.2)	14 (37.8)	37	**2.12**	**(1.08 – 4.18)**	**0.03**	**2.91**	**(1.31 – 6.49)**	**0.009**
	SE-negative RA n=269[++]								
	HLA-DRB1*03-	**HLA-DRB1*03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Healthy controls	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-	-			
Anti-MAA- Anti-CarP-	114 (85.7%)	19 (14.3)	133	**0.58**	**(0.35 – 0.96)**	**0.04**	1 (ref)	-	-
Anti-MAA+ Anti-CarP-	35 (58.3%)	25 (41.7)	60	**2.49**	**(1.46 - 4.23)**	**<0.001**	**4.29**	**(2.11 – 8.69)**	**<0.001**
Anti-MAA- Anti-CarP+	15 (51.7)	14 (48.3)	29	**3.25**	**(1.56 – 6.82)**	**0.002**	**5.60**	**(2.33 – 13.44)**	**<0.001**
Anti-MAA+ Anti-CarP+	31 (66.0)	16 (34.0)	47	1.80	(0.97 – 3.34)	0.06	**3.10**	**(1.43 – 6.72)**	**0.004**

[#]HLA-DRB1*03 data was present from 246 of 538 non-RA patients.
[##]HLA-DRB1*03 as well as anti-CarP and anti-AGE data was present from 301 of 648 RA patients.
[###]HLA-DRB1*03 as well as anti-CarP and anti-MAA data was present from 307 of 648 RA patients.
[+]HLA-SE as well as anti-CarP and anti-AGE data was present from 271 of 648 RA patients.
[++]HLA-SE as well as anti-CarP and anti-MAA data was present from 269 of 648 RA patients.
Statistically significant difference between patient group and healthy controls (p≤0.05)
Abbreviations: AGE, Advanced Glycation End-products; CarP, Carbamylated Protein; CCP2, citrullinated cyclic peptide 2; HLA-SE, human leukocyte antigen shared epitope; MAA, Malondialdehyde Acetaldehyde Adducts; RA, rheumatoid arthritis; 95%CI, 95% confidence interval.

Since HLA-DRB1*03 is associated with seronegative RA and anti-CarP antibodies in this disease subset, we sought to investigate the association of HLA-DRB1*03 with anti-AGE and anti-MAA. In RA patients HLA-DRB1*03 was more prevalent in anti-AGE-positive and anti-MAA-positive patients as compared to healthy controls with OR values of 1.34 (95% CI 1.01 to 1.78, p=0.05) and 1.29 (95% CI 0.96 to 1.73, p=0.09), although this did not achieve statistical significance compared to anti-AGE-negative or anti-MAA-negative patients respectively (*Table 2, part I*). To investigate whether HLA-DRB1*03 is associated with anti-MAA and anti-AGE in anti-CCP2-negative RA, we focused on this subset and stratified the analysis for anti-CarP. Within the anti-CCP2 negative RA patients, anti-AGE and anti-MAA antibodies were associated with HLA-DRB1*03 compared to healthy controls (OR: 1.98, 95% CI 1.27 to 3.07, p=0.003, and OR: 2.37, 95% CI 1.50 to 3.74, p<0.001, respectively). Anti-MAA was associated with HLA-DRB1*03 in the anti-CCP2 negative stratum independent of anti-CarP (OR: 1.91, 95% CI 1.11 to 3.30, p=0.02) (*Table 2, part II*). In this stratified analysis, anti-AGE showed the same trend for association but did not reach significance (OR: 1.48, 95% CI 0.86 to 2.52, p=0.16). Since anti-AGE and anti-MAA often co-occur, we next stratified the association analysis for these autoantibodies, to dissect whether the observed association to HLA-DRB1*03 could be attributed to one of them in particular. After stratification for anti-AGE or anti-MAA, only double positive RA patients showed a significant association with HLA-DRB1*03 compared to healthy controls (*Supplementary Table 2, part I*). Since some controversy exists on the association of HLA-DRB1*03 in anti-CCP2 negative RA patients, we investigated the association between anti-AGE and anti-MAA with HLA-DRB1*03 within HLA-SE negative RA patients. In both HLA-SE negative and anti-CCP2 negative stratum we find similar associations with anti-AGE/-MAA and HLA-DR1*03 (*Table 2, part III*).

In non-RA arthritis patients, both anti-AGE and anti-MAA showed a similar association with HLA-DRB1*03 with OR values of 2.34 (95% CI 1.58 to 3.47, p<0.001) and 1.94 (95% CI 1.29 to 2.92, p=0.002) compared to healthy controls (*Table 2, part I*). In a comparison within the non-RA arthritis patients, HLA DRB1*03 remained significantly associated with anti-AGE-positive compared to anti-AGE-negative patients (OR: 2.22, 95% CI 1.28 to 3.84, p=0.01), while the association with anti-MAA did not remain significant. To disentangle the effects of anti-AGE and anti-MAA, analyses were again stratified, after which only the presence of anti-AGE in anti-MAA-negative non-RA arthritis patients remained significantly associated with HLA-DRB1*03 (*Supplementary Table 2, part II*).

Taken together, these data indicate that anti-AGE and anti-MAA associate with HLA-DRB1*03 in RA and non-RA arthritis patients, and that this association (which cannot be ascribed to anti-AGE or anti-MAA in particular) is mainly present in anti-CCP2 negative RA patients. Similar associations were observed in HLA-SE negative RA patients.

Inflammation markers associate with anti-MAA positivity in RA and non-RA arthritis

Next we sought to investigate whether anti-PTM antibodies correlate with inflammation markers erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) (*Table 3*). Higher inflammation parameters in anti-AGE- and anti-MAA-positive individuals were observed in RA and non-RA arthritis patients, and in both the autoimmune and non-autoimmune subgroups of arthritis patients. To investigate whether both anti-MAA and anti-AGE were associated with acute phase reactants in RA independently, anti-AGE and anti-MAA were stratified for each other. After this stratification, anti-AGE was no longer associated with either CRP or ESR whereas the association of anti-MAA with these inflammation markers remained significant (*Supplementary Table 3)*. These data indicate that anti-PTM responses, especially anti-MAA, is associated with markers of inflammation in early arthritis in both RA and non-RA arthritis patients.

Anti-AGE and anti-MAA associate with radiological progression in anti-CCP2-negative RA patients

We next analyzed if the presence of anti-AGE and anti-MAA is associated with radiological progression in RA. Anti-AGE-positive patients displayed more radiographic damage per year than anti-AGE-negative patients (p<0.001) (*Figure 2A*). Data were then stratified for anti-CCP2, which revealed that this association was mainly present in the anti-CCP2-negative subgroup (*Figure 2B)*. When anti-CCP2 negative patients were further stratified for anti-CarP, the association between anti-AGE and radiographic progression remained significant (*Figure 2C)*. This indicates that in anti-CCP2 negative RA patients, anti-AGE is associated with radiological progression independent of anti-CarP, suggesting that this anti-PTM antibody could discriminate a different subgroup. Anti-MAA positivity was also associated with radiological progression (p=0.002) (*Figure 2D*). This effect was also observed in the anti-CCP2-negative stratum (Figure 2E), although no longer significant after stratifying for anti-CCP2. The latter could be a consequence of power as the effect size (beta) which decreased only slightly to 1.03/year, p=0.16 (*Figure 2E)*.

Presence of anti-MAA or anti-AGE is not associated with SDFR in RA

Next we sought to investigate whether anti-AGE and anti-MAA were associated with SDFR over time (*Supplementary Figure 1*). Anti-AGE was not associated with SDFR, hazard ratio (HR): 0.93 (95% CI 0.66 to 1.30; p=0.66) which did not differ after adjusting for CCP2 status (HR: 1.14, 95% CI 0.81 to 1.61, p=0.46). Anti-MAA-positive patients were less likely to achieve SDFR, compared to anti-MAA-negative patients, HR: 0.72 (95% CI 0.51 to 1.00, p=0.053). After adjusting for CCP2 status, there was no longer an association between anti-MAA and SDFR, HR: 1.05 (95% CI 0.74 to 1.50, p=0.80).

A.



Anti-AGE+	**1.05 (1.03, 1.07), p<0.001**	Anti-MAA+	**1.04 (1.01, 1.06), p=0.002**

D.



B.



E.



CCP2- Anti-AGE-	Reference		CCP2- Anti-MAA-	Reference	
CCP2+ Anti-AGE-	**1.12 (1.09, 1.16), p<0.001**	Reference	CCP2+ Anti-MAA-	**1.12 (1.09, 1.16), p<0.001**	Reference
CCP2- Anti-AGE+	**1.04 (1.003, 1.08), p=0.03**		CCP2- Anti-MAA+	1.03 (0.99, 1.06), p=0.16	
CCP2+ Anti-AGE+	**1.14 (1.11, 1.18), p<0.001**	1.02 (0.99, 1.05), p=0.26	CCP2+ Anti-MAA+	**1.13 (1.10, 1.16), p<0.001**	1.01 (0.97, 1.04), p=0.68

C.



CCP2- Anti-AGE-Anti-CarP-	Reference	
CCP2- Anti-AGE+Anti-CarP-	**1.04 (1.003, 1.95), p-0.027**	
CCP2- Anti-AGE-Anti-CarP+	1.04 (0.97, 1.12), p=0.26	Reference
CCP2- Anti-AGE+Anti-CarP+	**1.12 (1.06, 1.18), p<0.001**	**1.04 (10004, 1.92), p=0.03**

Figure 2: Anti-AGE and anti-MAA associate with radiological progression in RA patients (n=600). (A) radiological progression in anti-AGE positive and negative RA. (B) data stratified for CCP2. (C) data stratified for anti-CarP in anti-CCP2-negative stratum. (D) radiological progression in anti-MAA positive and negative RA. (E) data stratified for CCP2. Data presented as estimate (95%CI), p-value. *Abbreviations: AGE, Advanced Glycation End-product; CarP, Carbamylated Protein; CCP2, citrullinated cyclic peptide 2; MAA, Malondialdehyde Acetaldehyde Adduct.*

Table 3: Association between anti-AGE and anti-MAA antibodies and ESR and CRP levels.

	RA n=648*		non-RA n=538*		AI no RA n=233*		non-AI n=131*	
	ESR (median, IQR)	CRP (median, IQR)	ESR (median, IQR)	CRP (median, IQR)	ESR (median, IQR)	CRP (median, IQR)	ESR (median, IQR)	CRP (median, IQR)
n, % anti-AGE+	289 (44.6%)		177 (32.9%)		90 (38.6%)		31 (23.7%)	
Anti-AGE-	32.0 (19.0-52.8)	17.0 (7.0-36.0)	21.5 (9.0-41.0)	11.0 (3.8-29.0)	24.0 (10.0-47.0)	14.0 (4.0-32.0)	22.0 (9.0-93.0)	14.0 (4.0-34.0)
Anti-AGE+	38.0 (19.0-57.0)	19.0 (9.0-48.0)	39.0 (21.5-59.5)	19.0 (7.0-55.0)	43.5 (28.5-64.8)	21.0 (9.0-56.0)	42.0 (26.0-55.0)	25.0 (6.5-93.0)
p-value	**0.02**	**0.03**	**<0.001**	**<0.001**	**<0.001**	**0.004**	**0.001**	0.095
n, % anti-MAA+	299 (46.1%)		163 (30.3%)		96 (41.2%)		19 (14.5%)	
Anti-MAA-	30.0 (16.8-48.3)	15.0 (6.0-31.0)	20.5 (9.0-39.0)	10.0 (3.0-27.0)	25.0 (10.0-45.0)	13.0 (4.0-32.0)	22.0 (11.0-41.0)	13.8 (4.0-34.0)
Anti-MAA+	41.0 (22.0-61.5)	22.5 (10.0-48.3)	42.0 (27.0-61.0)	21.0 (9.0-48.8)	44.5 (27.0-62.5)	21.5 (8.8-56.0)	45.0 (31.0-58.0)	25.0 (9.0-79.2)
p-value	**<0.001**	**<0.001**	**<0.001**	**<0.001**	**<0.001**	**0.003**	**0.005**	0.06

*ESR and CRP levels were not determined for all patients and numbers might therefore slightly differ per variable

Statistically significant difference between groups (p≤0.05)

Abbreviations: AGE, Advanced Glycation End-products; AI, Autoimmune (RA, psoriatic arthritis, paramalignant arthritis, SLE, sarcoidosis, spondyloarthropathy); CRP, C-reactive protein;

ESR, erythrocyte sedimentation rate; IQR, interquartile range; MAA, Malondialdehyde Acetaldehyde Adducts; non-AI, non-autoimmune (septic arthritis, gout and pseudogout);

RA, rheumatoid arthritis.

Discussion

In this study we demonstrated that anti-AGE and anti-MAA are present in RA patients, and interestingly also in a substantial part of otherwise seronegative RA patients. This is not specific for RA, as anti-AGE and anti-MAA antibodies were also present in other forms of early arthritis. Both anti-AGE and anti-MAA are associated with HLA-DRB1*03 in RA, and anti-AGE is also associated with HLA-DR1*03 in non-RA arthritis patients. Anti-AGE and anti-MAA are associated with a distinct clinical phenotype: anti-AGE associates with radiological progression in RA whereas anti-MAA only showed a trend with radiological progression but associated with increased inflammatory parameters in both RA and non-RA arthritis.

Associations with particular HLA class II alleles have been described to occur in many seropositive auto-immune diseases (13, 14). More specifically, HLA-DRB1*03, initially reported to be associated with anti-CCP2 negative RA, was later associated with presence of anti-CarP, although not all HLA DRB1*03-positive patients were anti-CarP-

positive (10, 12). In this study we observed that HLA-DRB1*03 was associated with anti-AGE and anti-MAA in anti-CCP2 negative RA patients which was independent of anti-CarP, thereby identifying another subgroup of anti-CCP2 negative RA that is associated with HLA-DRB1*03. In addition, anti-AGE associated with HLA-DRB1*03 in non-RA arthritis confirming the robustness of this finding. Together, these observations provide additional insight into the association of HLA DBR1*03 with (rheumatoid) arthritis; although these alleles are not associated with the presence of ACPA, they do appear to predispose to the formation of other autoantibodies (anti-CarP, anti-AGE and anti-MAA) in a process in which HLA class II-associated T-cell-dependent immune responses are likely to be involved.

Interestingly, in RA, anti-AGE associated with radiological progression independent of anti-CCP2 and anti-CarP suggesting an additive value of anti-AGE in determining disease evolution as it could define a new subgroup of RA patients. Strikingly, anti-AGE was not associated with SDFR. In RA and non-RA arthritis, a subgroup of patients is characterized by more extensive inflammation and the presence of anti-MAA antibodies, while a subgroup of CCP2 negative RA patients is characterized by radiological progression and presence of anti-AGE antibodies. Based on these results distinct subgroups within RA and non-RA arthritis can be delineated based on their specific clinical phenotype.

The presence of AGE modified proteins and anti-AGE antibodies has been observed in diabetes and hypertension (6, 23). Also in synovial tissue and sera of RA patients, AGE-modified proteins have been detected (24-26). In addition, MAA-modified proteins have been observed before in RA tissue (7) and it is clear that both modifications can be induced by inflammation and oxidative stress in the inflamed joint (5, 7). Our study now adds that in a subset of the RA patients antibodies against these PTMs are present. Additionally, anti-AGE and anti-MAA have been found to be associated with ESR in previous studies in RA and SLE (22). PTMs and anti-PTMs such as anti-AGE and anti-MAA add to the understanding that the combined presence of the antigen and the antibody could trigger effector mechanisms and contribute to the overall process of arthritis and joint damage, in RA and also in non-RA arthritis. It would therefore be interesting to investigate whether next to carbamylated proteins (27) also the modifications AGE and MAA are present in cartilage and synovium. Additionally, experimental pathogenicity studies on anti-AGE and anti-MAA specifically should be performed to elucidate on the contribution of these anti-PTM antibodies to pathogenesis.

There are some limitations to our study. Data on anti-CarP antibody levels was missing for 149 RA patients, therefore analysis using stratification including anti-CarP could only be performed in a subgroup of all RA patients. However, this group still consists of 499 RA patients and therefore still appears a good representation of the RA population.

Radiological progression was assessed in 635 RA patients included before 2006. Thereafter, radiographs have not been scored since radiographic damage has become rare/nearly non-existent with current treatment strategies. This effectively enabled us to detect differences in the, earlier, informative part of the cohort. When stratifying radiological progression data, groups became small and therefore could suffer from insufficient power implicating that significance could not always be reached. It is therefore important to verify associations using different and/or bigger cohorts to be able to generalize findings to the whole RA population. Additionally, in order to verify the results obtained in this study, a replication cohort is needed. In such a study IgA and IgM responses could be included to elaborate on the full anti-PTM antibody responses in (rheumatoid) arthritis patients (28, 29). One of the strengths of this study is that the EAC is a well-defined cohort containing RA and non-RA early arthritis patients with extensive information on the HLA haplotype and radiological progression for RA patients (15). Secondly, antibody responses have been investigated on the PTM-modified proteins and their control proteins. All PTMs were created on the same antigen backbone and reactivity against FCS itself was subtracted from the results. This results in reliable measurements that capture truly PTM-specific signals and decreases the chance of false observations (30). Additionally, correlation analyses were performed (data not shown) and data was stratified for the other investigated anti-PTM and to verify that anti-AGE and anti-MAA are solely responsible for the observed result and not cross-reactive.

In conclusion, anti-AGE and anti-MAA antibodies are both prevalent in RA patients, and other inflammatory rheumatic conditions, and although not specific for RA they each correlate with specific parameters. Anti-MAA associates with HLA-DRB1*03 in CCP2 negative (RA) patients independent of anti-CarP and associates with inflammation. Anti-AGE associates with HLA-DRB1*03 in CCP2- negative RA patients and is associated with a worse radiological progression especially in anti-CCP2- and anti-CarP-negative RA patients. With this study we have now characterized a seropositive subgroup within the heterogeneous group of RA patients that have been thus far been considered seronegative.

Acknowledgements

We thank Marloes Verstappen and Bianca M. Boxma-de Klerk for their assistance regarding the remission analysis on EAC cohort data.

References

1. Trouw LA, Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev. 2012;12(2):318-22.
2. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998;101(1):273-81.
3. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A. 2011;108(42):17372-7.
4. Xu H, Wang Y, Lin S, Deng W, Peng D, Cui Q, et al. PTMD: A Database of Human Disease-associated Post-translational Modifications. Genomics Proteomics Bioinformatics. 2018;16(4):244-51.
5. Schmidt AM, Du Yan S, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. Journal of Clinical Investigation. 2001;108(7):949-55.
6. Nikolov A, Blazhev A, Tzekova M, Kostov K, Popovski N. Serum Levels of Antibodies to Advanced Glycation End Products in Patients with Type 2 Diabetes Mellitus and Hypertension. Folia Med (Plovdiv). 2020;62(2):295-301.
7. Thiele GM, Duryee MJ, Anderson DR, Klassen LW, Mohring SM, Young KA, et al. Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(3):645-55.
8. Buongiorno AM, Morelli S, Sagratella E, Cipriani R, Mazzaferro S, Morano S, et al. Immunogenicity of advanced glycation end products in diabetic patients and in nephropathic non-diabetic patients on hemodialysis or after renal transplantation. J Endocrinol Invest. 2008;31(6):558-62.
9. Thiele GM, Tuma DJ, Willis MS, Miller JA, McDonald TL, Sorrell MF, et al. Soluble proteins modified with acetaldehyde and malondialdehyde are immunogenic in the absence of adjuvant. Alcohol Clin Exp Res. 1998;22(8):1731-9.
10. Verpoort KN, van Gaalen FA, van der Helm-van Mil AH, Schreuder GM, Breedveld FC, Huizinga TW, et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum. 2005;52(10):3058-62.
11. Regueiro C, Rodriguez-Rodriguez L, Triguero-Martinez A, Nuno L, Castano-Nunez AL, Villalva A, et al. Specific Association of HLA-DRB1*03 With Anti-Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019;71(3):331-9.
12. Jiang X, Trouw LA, van Wesemael TJ, Shi J, Bengtsson C, Kallberg H, et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis. 2014;73(10):1761-8.
13. Kirino Y, Remmers EF. Genetic architectures of seropositive and seronegative rheumatic diseases. Nat Rev Rheumatol. 2015;11(7):401-14.
14. Cruz-Tapias P, Perez-Fernandez OM, Rojas-Villarraga A, Rodriguez-Rodriguez A, Arango MT, Anaya JM. Shared HLA Class II in Six Autoimmune Diseases in Latin America: A Meta-Analysis. Autoimmune Dis. 2012;2012:569728.
15. de Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Predicting arthritis outcomes--what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford). 2011;50(1):93-100.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
17. van Aken J, van Bilsen JH, Allaart CF, Huizinga TW, Breedveld FC. The Leiden Early Arthritis Clinic. Clin Exp Rheumatol. 2003;21(5 Suppl 31):S100-5.
18. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005;52(11):3433-8.
19. Knevel R, Krabben A, Brouwer E, Posthumus MD, Wilson AG, Lindqvist E, et al. Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study. Ann Rheum Dis. 2012;71(10):1651-7.
20. van der Heijde DM. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;(1):261-3.
21. Verstappen M, van Steenbergen HW, de Jong PHP, van der Helm-van Mil AHM. Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution. Arthritis Res Ther. 2022;24(1):4.
22. Monahan RC, van den Beukel MD, Borggreven NV, Fronczek R, Huizinga TWJ, Kloppenburg M, et al. Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations. RMD Open. 2022;8(1).

23. Aso Y, Inukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol. 2000;37(2):87-92.
24. Drinda S, Franke S, Canet CC, Petrow P, Brauer R, Huttich C, et al. Identification of the advanced glycation end products N(epsilon)-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61(6):488-92.
25. de Groot L, Hinkema H, Westra J, Smit AJ, Kallenberg CG, Bijl M, et al. Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. Arthritis Res Ther. 2011;13(6):R205.
26. Ligier S, Fortin PR, Newkirk MM. A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. Br J Rheumatol. 1998;37(12):1307-14.
27. Verheul MK, Janssen GMC, de Ru A, Stoeken-Rijsbergen G, Levarht EWN, Kwekkeboom JC, et al. Mass-spectrometric identification of carbamylated proteins present in the joints of rheumatoid arthritis patients and controls. Clin Exp Rheumatol. 2021;39(3):570-7.
28. van Delft MAM, van der Woude D, Toes REM, Trouw LA. Secretory form of rheumatoid arthritis-associated autoantibodies in serum are mainly of the IgM isotype, suggesting a continuous reactivation of autoantibody responses at mucosal surfaces. Ann Rheum Dis. 2019;78(1):146-8.
29. Mikuls TR, Duryee MJ, England BR, Anderson DR, Hearth-Holmes M, Su K, et al. Malondialdehyde-acetaldehyde antibody concentrations in rheumatoid arthritis and other rheumatic conditions. Int Immunopharmacol. 2018;56:113-8.
30. Ahlin E, Elshafie AI, Nur MA, Ronnelid J. Anti-citrullinated peptide antibodies in Sudanese patients with Leishmania donovani infection exhibit reactivity not dependent on citrullination. Scand J Immunol. 2015;81(3):201-8.

Supplementary files

Supplementary Table 1: Prevalence of antibodies against AGE and MAA in healthy controls (n= 80) versus RA (n=648), non-RA (n=538), AI no RA (n=234) and non-AI (n=166) patient groups.

	Anti-AGE		**Anti-MAA**	
	aU/mL	***n, % positive***	**aU/mL**	***n, % positive***
HC (n=80)	94,2 [52,7 – 160,6]	6 (7,5)	358,4 [282,4 – 480,8]	3 (3,8)
RA (n=648)	233,1 [130,4 – 367,4]	289 (44,6)*	931,8 [663,2 – 1277,4]*	299 (46,1)*
non-RA (n=538)	177,8 [93,8 – 309,4]	177 (32,9)*	728,3 [485,1 – 1111,0]*	163 (30,3)*
AI no RA (n=234)	192,6 [102,3 – 328,6]	90 (38,5)*	853,7 [592,1 – 1246,5]*	97 (41,5)*
non-AI (n=166)	171,0 [107,2 – 286,4]	46 (27,7)*	666,1 [485,5 – 922,4]*	33 (19,9)*

Results are presented as median [IQR] and n (%)

* Statistically significant difference between patient group and healthy controls (p≤0.001)

Abbreviations: AGE, advanced glycation end-product; AI, Autoimmune (including psoriatic arthritis, paraneoplastic arthritis, SLE, sarcoidosis and spondyloarthritis); HC, Healthy controls; IQR, interquartile range; *MAA, malondialdehyde-acetaldehyde adduct; non-AI, non-autoimmune (including septic arthritis, gout, pseudogout); RA rheumatoid arthritis.*

Supplementary Table 2: Association anti-AGE and anti-MAA responses with HLA-DRB1*03 cross stratified for anti-AGE and anti-MAA for RA in part I and non-RA arthritis in part II.

Part I		RA n=648								
		HLA-DRB1*03-	**HLA-DRB1*03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Anti-AGE-	**Healthy controls**	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-	-	-	-	-
	Anti-MAA-	203 (75.5%)	66 (24.5%)	269	1.13	(0.83, 1.54)	0.43	-	-	-
	Anti-MAA+	68 (75.6%)	22 (24.4%)	90	1.13	(0.68, 1.86)	0.64	-	-	-
		HLA-DRB1.03-	**HLA-DRB1.03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Anti-AGE+	**Healthy controls**	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-	-	-	-	-
	Anti-MAA-	63 (78.8%)	17 (21.3%)	80	0.94	(0.54, 1.63)	0.83	1 (ref)	-	-
	Anti-MAA+	148 (70.8%)	61 (29.2%)	209	**1.44**	**(1.04, 1.99)**	**0.03**	1.53	(0.83, 2.82)	0.18
		HLA-DRB1*03-	**HLA-DRB1*03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Anti-MAA-	**Healthy controls**	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-	-	-	-	-
	Anti-AGE-	203 (75.5%)	66 (24.5%)	269	1.13	(0.83, 1.54)	0.43	-	-	-
	Anti-AGE+	63 (78.8%)	17 (21.3%)	80	0.94	(0.54, 1.63)	0.83	**-**	**-**	**-**
		HLA-DRB1.03-	**HLA-DRB1.03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Anti-MAA+	**Healthy controls**	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-	-	-	-	-
	Anti-AGE-	68 (75.6%)	22 (24.4%)	90	1.13	(0.68, 1.86)	0.64	1 (ref)	-	-
	Anti-AGE+	148 (70.8%)	61 (29.2%)	209	**1.44**	**(1.04, 1.99)**	**0.03**	1.27	(0.72, 2.24)	0.40

Supplementary Table 2: Continued.

Part II		**non-RA n=246**								
		HLA-DRB1*03-	**HLA-DRB1*03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Anti-AGE-	**Healthy controls**	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-	-	-	-	-
	Anti-MAA-	77 (78.6%)	21 (21.4%)	98	0.95	(0.58, 1.57)	0.84	1 (ref)	-	-
	Anti-MAA+	22 (71.0%)	9 (29.0%)	31	1.43	(0.65, 3.13)	0.38	1.50	(0.60, 3.74)	0.38
		HLA-DRB1.03-	**HLA-DRB1.03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Anti-AGE+	**Healthy controls**	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-	-	-	-	-
	Anti-MAA-	20 (55.6%)	16 (44.4%)	36	**2.79**	**(1.43, 5.46)**	**0.003**	1 (ref)	-	-
	Anti-MAA+	50 (61.7%)	31 (38.5%)	81	**2.16**	**(1.35, 3.45)**	**0.001**	0.78	(0.35, 1.72)	0.53
		HLA-DRB1*03-	**HLA-DRB1*03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Anti-MAA-	**Healthy controls**	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-	-	-	-	-
	Anti-AGE-	77 (78.6%)	21 (21.4%)	98	0.95	(0.58, 1.57)	0.84	1 (ref)	-	-
	Anti-AGE+	20 (55.6%)	16 (44.4%)	36	**2.79**	**(1.43, 5.46)**	**0.003**	**2.93**	**(1.30, 6.63)**	**0.01**
		HLA-DRB1.03-	**HLA-DRB1.03+**	**Total**	**OR**	**95%CI**	**p-value**	**OR**	**95%CI**	**p-value**
Anti-MAA+	**Healthy controls**	941 (77.7%)	270 (22.3%)	1211	1 (ref)	-	-	-	-	-
	Anti-AGE-	22 (71.0%)	9 (29.0%)	31	1.43	(0.65, 3.13)	0.38	1 (ref)	-	-
	Anti-AGE+	50 (61.7%)	31 (38.5%)	81	**2.16**	**(1.35, 3.45)**	**0.001**	1.52	(0.62, 3.71)	0.36

Results are presented as n (%) and OR (95% confidence interval)
Statistically significant difference between patient group and healthy controls (p≤0.05)
Abbreviations: AGE, advanced glycation end-product; MAA, malondialdehyde-acetaldehyde adduct; HC, Healthy controls; RA rheumatoid arthritis.

Supplementary Table 3: Association anti-PTM responses with ESR and CRP cross stratified for anti-AGE and anti-MAA for RA and non-RA arthritis.

RA	Anti-AGE-			Anti-AGE+			Anti-MAA-			Anti-MAA+		
	Anti-MAA- n=267	Anti-MAA+ n=89	p-value	Anti-MAA- n=79	Anti-MAA+ n=208	p-value	Anti-AGE- n=267	Anti-AGE+ n=79	p-value	Anti-AGE- n=89	Anti-AGE+ n=208	p-value
ESR (median, IQR)	30.0 (16.0-49.0)	41.0 (22.5-57.0)	**0.009**	30.0 (18.0-47.0)	41.0 (20.0-64.8)	**0.010**	30.0 (16.0-49.0)	30.0 (18.0-47.0)	0.83	41.0 (22.5-57.0)	41.0 (20.0-64.8)	0.72
CRP (median, IQR)	15.0 (6.0-33.0)	24.0 (10.0-41.8)	**0.008**	12.0 (8.0-29.0)	22.0 (9.8-52.3)	**0.005**	15.0 (6.0-33.0)	12.0 (8.0-29.0)	0.81	24.0 (10.0-41.8)	22.0 (9.8-52.3)	0.77

non-RA	Anti-AGE-			Anti-AGE+			Anti-MAA-			Anti-MAA+		
	Anti-MAA- n= 302*	Anti-MAA+ n=54*	p-value	Anti-MAA- n=68*	Anti-MAA+ n=109*	p-value	Anti-AGE- n=302*	Anti-AGE+ n=68*	p-value	Anti-AGE- n=54*	Anti-AGE+ n=109*	p-value
ESR (median, IQR)	17.5 (8.0-36.0)	38.5 (23.0-63.5)	**<0.001**	31.0 (14.0 – 55.8)	42.00 (27.0-60.5)	**0.05**	17.5 (8.0-36.0)	31.0 (14.0 – 55.8)	**<0.001**	38.5 (23.0-63.5)	42.0 (27.0-60.5)	0.59
CRP (median, IQR)	9.0 (3.0-25.8)	21.0 (9.0-44.0)	**<0.001**	15.9 (5.0- 48.3)	21.0 (8.7-55.5)	0.09	9.0 (3.0-25.8)	15.9 (5.0- 48.3)	**0.05**	21.0 (9.0-44.0)	21.0 (8.7-55.5)	0.66

Results are presented as median (IQR)
*ESR and CRP levels were not determined for all patients and numbers might therefore slightly differ per variable
Statistically significant difference between groups (p≤0.05)
Abbreviations: AGE, Advanced Glycation End-products; *CRP,* C-reactive protein; *ESR,* erythrocyte sedimentation rate; *IQR,* interquartile range; *MAA,* Malondialdehyde Acetaldehyde Adducts*; RA,* rheumatoid arthritis.



Supplementary Figure 1: Presence of anti-MAA or anti-AGE is not associated with SDFR in RA patients (n=624). (A) Kaplan Meier curves presenting percentage remission in anti-AGE positive and -negative RA. (B) left panel: percentage remission in anti-MAA positive and -negative RA. Right panel: data stratified for CCP2 status. The number of patients entering the time interval is shown under each graph. *Abbreviations: AGE, Advanced Glycation End-product; CarP, Carbamylated Protein; CCP2, citrullinated cyclic peptide 2; MAA, Malondialdehyde-Acetaldehyde Adduct.*